GlycoVaxyn has built a broad portfolio of conjugate vaccines against common severe bacterial infections based on its unique, proprietary invivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spinout of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland.
Funding Rounds (2) - $22.1MUpdate
Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35...
Index Ventures is a multi-stage international venture capital firm with deep sector expertise...
Edmond de Rothschild Venture Capital invests in companies involved in the human health industry.